Navigation Links
SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008

DUBLIN, Calif., Sept. 8 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that Michael Molkentin, Chief Financial Officer, and Michael V. McCullar, Ph.D., Vice President of Drug Discovery Operations, are scheduled to co-present at the Merriman 5th Annual Investor Summit on Monday, September 15, 2008 at the Mark Hopkins Hotel in San Francisco.

SuperGen's presentation at the Merriman Investor Summit is scheduled to begin at 8:30 a.m. PDT (11:30 a.m. EDT). A live webcast of the presentation will be available on the investor relations section of the Company's Web site at A webcast replay of the presentation will be available shortly following the live event.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit .


SuperGen, Inc.

Timothy L. Enns

SVP, Corporate Communications

& Business Development

Tel: (925) 560-0100


Mary M. Vegh

Manager, Investor Relations

Tel: (925) 560-2845


Dorland Global Public Relations

Michael Beckerich (Media)

Tel: (212) 677-7632

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. SuperGen Reports 2008 Second Quarter Financial Results
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
(Date:11/24/2015)... 24, 2015 --> ... report released by Transparency Market Research, the global non-invasive ... CAGR of 17.5% during the period between 2014 and ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ... testing market to reach a valuation of US$2.38 bn ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use ... promoted Melanie Aregger to serve as Chief Operating Officer. , Having joined ... management team and was promoted to Head of InSphero Diagnostics in 2014. ...
(Date:11/24/2015)... 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... president and chief executive officer, will present at the 27 ... New York City . The presentation will ... 2015 at 9:30 a.m. EST. and ... at least 15 minutes prior to the presentation to allow ...
(Date:11/23/2015)... THOUSAND OAKS, Calif., Nov. 23, 2015   Ceres, ... company, announced today financial results for the fiscal year ... its business. --> --> ... on commercializing forage and feed products with a better ... the company signed distribution agreements with several leading crop ...
Breaking Biology Technology:
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
Breaking Biology News(10 mins):